_________
false
ôìåøéñèí úøôéåèé÷ñ àéð÷
2
381
PLURISTEM THERAPEUTICS INC
Corporation no:
C12337-2001
8544
Israel Securities Authority
Tel Aviv Stock Exchange
C003
(
Public
)
Reported via MAGNA:
26/10/2017
www.isa.gov.il
www.tase.co.il
Reference:
2017-02-094228
Time of broadcast:
13:55
13:48:02
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Following Approval of Israel’s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel
MOH_Approval_for_PLX-R18_Phase_I_Trial_final_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
25/09/2017
Address:
Matam Park
5
,
Haifa
31905
ISRAEL
,
Tel:
074-7107171
,
Fax:
074-7107172
E-mail address:
Info@Pluristem.Com
Company site:
www.pluristem.com
Previous names of reporting entity:
Name of the Signatory:
Aberman Zalman
Position of Signatory in the reporting corporation:
Chairman Of The Board & CEO
Name of Employer Company:
Address:
Matam Park
20
,
Haifa
31905
Telephone:
074-7107171
Facsimile:
074-7107172
E-mail:
zami@pluristem.com
2